866-997-4948(US-Canada Toll Free)

Oropharyngeal Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Cancer

No. of Pages : 79 Pages


Oropharyngeal Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Oropharyngeal Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Oropharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oropharyngeal Cancer. Oropharyngeal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Oropharyngeal Cancer.
  • A review of the Oropharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Oropharyngeal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Oropharyngeal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oropharyngeal Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Oropharyngeal Cancer 9
Oropharyngeal Cancer Therapeutics under Development by Companies 11
Oropharyngeal Cancer Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Oropharyngeal Cancer Therapeutics Products under Development by Companies 18
Oropharyngeal Cancer Therapeutics Products under Investigation by Universities/Institutes 19
Companies Involved in Oropharyngeal Cancer Therapeutics Development 20
Advaxis, Inc. 20
Oropharyngeal Cancer Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ADXS-HPV - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cisplatin + Radiation Therapy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
HPPH - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
cisplatin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cisplatin + Radiation Therapy1 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Radiation Therapy + Cetuximab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 43
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 45
Cisplatin + Erlotinib + Radiation Therapy - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Vorinostat + Cisplatin + Radiation Therapy - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 50
S-1 + Radiation Therapy - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
minocycline - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Docetaxel + Radiation Therapy - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cetuximab + Docetaxel + Cisplatin + 5-FU - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cetuximab + Cisplatin + Docetaxel + 5-FU - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 60
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Erbitux + Docetaxel + Cisplatin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Lapatinib Ditosylate + Capecitabine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Taxotere + Cisplatin + 5-FU - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Erbitux + Radiation Therapy - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Docetaxel + Cisplatin + Fluorouracil + Carboplatin + Cetuximab + Radiation Therapy - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 72
Oropharyngeal Cancer Therapeutics Drug Profile Updates 73
Oropharyngeal Cancer Therapeutics Discontinued Products 76
Oropharyngeal Cancer Therapeutics - Dormant Products 77

Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

List of Table


Number of Products Under Development for Oropharyngeal Cancer, H2 2012 9
Products under Development for Oropharyngeal Cancer Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Advaxis, Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Oropharyngeal Cancer Therapeutics Drug Profile Updates 73
Oropharyngeal Cancer Therapeutics Discontinued Products 76
Oropharyngeal Cancer Therapeutics Dormant Products 77

List of Chart


Number of Products under Development for Oropharyngeal Cancer, H2 2012 9
Products under Development for Oropharyngeal Cancer Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *